Vor Biopharma FY2030 EPS Forecast Reduced by HC Wainwright

Key Points

• HC Wainwright lowered Vor Biopharma’s FY2030 EPS forecast to $3.89 from $4.27, while maintaining a “Buy” rating and a $31 price target.
• Vor Biopharma reported quarterly EPS of -$0.80, missing the consensus estimate of -$0.69. Analysts’ overall view remains “Moderate Buy,” with a consensus price target of $43.38.
• The stock opened at $22.34, versus a 12-month range of $6.50 to $50.20, and institutional investors own a substantial 97.29% of outstanding shares.

Vor Biopharma Inc. (NASDAQ:VOR - Free Report) - HC Wainwright cut their FY2030 earnings per share (EPS) estimates for Vor Biopharma in a research note issued to investors on Wednesday, August 12th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of $3.89 per share for the year, down from their previous estimate of $4.27. HC Wainwright has a "Buy" rating and a $31.00 price objective on the stock. The consensus estimate for Vor Biopharma's current full-year earnings is ($2.51) per share.

VOR has been the topic of several other research reports. Weiss Ratings upgraded shares of Vor Biopharma from a "sell (d-)" rating to a "sell (d+)" rating in a report on Tuesday. Wall Street Zen lowered Vor Biopharma from a "hold" rating to a "sell" rating in a research report on Saturday, May 16th. Wedbush upped their price target on Vor Biopharma from $18.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday. Finally, Jefferies Financial Group upgraded Vor Biopharma to a "strong-buy" rating in a report on Thursday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $43.38.

Vor Biopharma Stock Performance

NASDAQ:VOR opened at $22.34 on Thursday. Vor Biopharma has a 12 month low of $6.50 and a 12 month high of $50.20. The firm has a fifty day simple moving average of $18.18 and a two-hundred day simple moving average of $15.91.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11).

Institutional Trading of Vor Biopharma

Several institutional investors and hedge funds have recently made changes to their positions in the company. RA Capital Management L.P. increased its stake in Vor Biopharma by 172.7% in the 4th quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company's stock valued at $70,697,000 after buying an additional 3,422,697 shares during the last quarter. Fcpm Iii Services B.V. boosted its stake in shares of Vor Biopharma by 852.8% in the 4th quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company's stock worth $47,315,000 after buying an additional 3,237,714 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new position in shares of Vor Biopharma in the 4th quarter worth approximately $33,275,000. Paradigm Biocapital Advisors LP bought a new position in shares of Vor Biopharma in the fourth quarter valued at approximately $22,890,000. Finally, NEXTBio Capital Management LP bought a new position in shares of Vor Biopharma in the fourth quarter valued at approximately $13,080,000. Hedge funds and other institutional investors own 97.29% of the company's stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company's proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient's immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source